BCRP/ABCG2 inhibitors: a patent review (2009 – present)

Bibliography

• Bodo A, Bakos E, Szeri F, et al. The role of multidrug transporters in drug availability. metabolism and toxicity. Toxicol Lett 2003;140-141:133-43
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34
   PubMed Web of Science ®Google Scholar
• Hipfner DR, Deeley RG; Cole SPC. Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1999;1461:359-76
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006;25:231-59
   PubMed Web of Science ®Google Scholar
• Eckford PD, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009;109:2989-3011
   PubMed Web of Science ®Google Scholar
• Szakacs G, Hall MD, Gottesman MM, et al. Targeting the achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev 2014;114:5753-74
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295-302
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-58
   PubMed Web of Science ®Google Scholar
• Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-62
   PubMed Web of Science ®Google Scholar
• Carlsen SA, Till JE, Ling V. Modulation of membrane drug permeability in Chinese hamster ovary cells. Biochim Biophys Acta 1976;455:900-12
   PubMed Web of Science ®Google Scholar
• Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4
   PubMed Web of Science ®Google Scholar
• Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch 2007;453:621-41
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Tirona RG, Kim RB. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003;2:685-98
   PubMed Web of Science ®Google Scholar
• Burger H, Nooter K, Zaman GJ, et al. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994;8:990-7
   PubMed Web of Science ®Google Scholar
• Nooter K, Westerman AM, Flens MJ, et al. Expression of the multidrug resistance associated protein (MRP) gene in human cancers. Clin Cancer Res 1995;1:1301-10
   PubMed Web of Science ®Google Scholar
• Kruh GD, Gaughan KT, Godwin A, et al. Expression pattern of MRP in human tissues and adult solid tumor cell lines. J Natl Cancer Inst 1995;87:1256-8
   PubMed Web of Science ®Google Scholar
• Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 2006;27:438-46
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Leier I, Buchholz U, et al. Transport of glutathione, glucuronate, and sulphate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 1996;56:988-94
   PubMed Web of Science ®Google Scholar
• Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998;95:15665-70
   PubMed Web of Science ®Google Scholar
• Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008;9:105-27
   PubMed Web of Science ®Google Scholar
• Allen JD, van Loevezijn A, Lakhai JM, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-25
   PubMed Web of Science ®Google Scholar
• Shiozawa K, Oka M, Soda H, et al. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int J Cancer 2004;108:146-51
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Bokesch HR, Dean M, et al. A high-throughput cell-based assay for inhibitors of ABCG2 activity. J Biomol Screen 2006;11:176-83
   PubMed Web of Science ®Google Scholar
• Robey RW, Steadman K, Polgar O, et al. Cancer Res 2004;64:1242-6
   PubMed Web of Science ®Google Scholar
• Maliepaard M, van Gastelen MA, Tohgo A, et al. Clin Cancer Res 2001;7:935-41
   PubMed Web of Science ®Google Scholar
• Pick A, Mueller H, Wiese M. Bioorg Med Chem 2008;16:8224-36
   PubMed Web of Science ®Google Scholar
• Kühnle M, Egger M, Müller C, et al. Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from the p-Glycoprotein (ABCB1) Modulator Tariquidar. J Med Chem 2009;52:1190-7
   PubMed Web of Science ®Google Scholar
• Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. Br J Cancer 2008;98:857-62
   PubMed Web of Science ®Google Scholar
• Juvale K, Wiese M. 4-Substituted-2-phenylquinazolines as inhibitors of BCRP. Bioorg Med Chem Lett 2012;22:6766-9
   PubMed Web of Science ®Google Scholar
• Juvale K, Gallus J, Wiese M. Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 2013;21:7858-73
   PubMed Web of Science ®Google Scholar
• Pick A, Müller H, Mayer R, et al. Structure–activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 2011;19:2090-102
   PubMed Web of Science ®Google Scholar
• Yan HC, Fang LS, Xu J, et al. The identification of the biological characteristics of human ovarian cancer stem cells. Eur Rev Med Pharmacol Sci 2014;18:3497-503
   PubMed Web of Science ®Google Scholar
• Garson K, Vanderhyden BC. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. Reproduction 2015;149:R59-70
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Bokesch HR, Bates SE, et al. Method of inhibiting abcg2 and related treatments. WO061770; 2009
   Google Scholar
• Henrich CJ, Robey RW, Bokesch HR, et al. New inhibitors of ABCG2 identified by high-throughput screening. Mol Cancer Ther 2007;6:3271-8
   PubMed Web of Science ®Google Scholar
• Yamazaki R, Hatano H, Yaegashi T, et al. Abcg2 inhibitor. EP 2218719; 2010
   Google Scholar
• Aiyama R, Furuta T, Hashimoto S, et al. Bcrp/abcp2 inhibitor. WO106778; 2006
   Google Scholar
• Larson RS, Sklar LA, Edwards BS, et al. Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors. US0208493; 2009
   Google Scholar
• Chow LMC, Chan TH, Chan KF, et al. Alkyne-, azide- and triazole-containing flavonoids as modulators for multidrug resistance in cancers. WO127361; 2013
   Google Scholar
• Chan KF, Zhao Y, Chow TW, et al. Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships. ChemMedChem 2009;4:594-614
   PubMed Web of Science ®Google Scholar
• Kuriakose J, Hrycyna CA, Chmielewski J. Click chemistry-derived bivalent quinine inhibitors of P-glycoprotein-mediated cellular efflux. Bioorg Med Chem Lett 2012;22:4410-12
   PubMed Web of Science ®Google Scholar
• Chen Z-S, Shi Z, Ashby CR. Use of phosphodiesterase inhibitors for treating multidrug resistance. US0288078; 2014
   Google Scholar
• Vellonen KS, Mannermaa E, Turner H, et al. Effluxing ABC transporters in human corneal epithelium. J Pharm Sci 2010;99:1087-98
   PubMed Web of Science ®Google Scholar
• Karla PK, Mangat HS. Method of treating an ocular disease and compositions effective for treating an ocular disease. WO158296; 2013
   Google Scholar
• Pomper MG, Zhang Y, Laterra J. Bioluminescence imaging-based screening assay and inhibitors of abcg2. US0250129; 2011
   Google Scholar
• Zhang Y, Bressler JP, Neal J, et al. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res 2007;67:9389-97
   PubMed Web of Science ®Google Scholar
• Henrich CJ, Bokesch HR, Cartner LK, et al. Method of inhibiting abcg2 and other treatment methods. US0274323; 2013
   Google Scholar
• Kottgen M, Coresh J, Guggino W, et al. Modulation of abcg2-mediated urate transport to treat hyperuricemia and gout. US0010102; 2012
   Google Scholar
• Anzai N, Kanai Y, Endou H. New insights into renal transport of urate. Curr Opin Rheumatol 2007;19:151-7
   PubMed Web of Science ®Google Scholar
• Dehghan A, Köttgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008;372:1953-61
   PubMed Web of Science ®Google Scholar
• Chu P, Robert Peach R. Cancer stem cells expressing abcg2. US0244268; 2013
   Google Scholar
• Sugimoto Y, Katayama K. Prophylactic and Therapeutic Agent for Cancer. US0239936; 2009
   Google Scholar